Author: Beigel, John H.; Tebas, Pablo; Elie-Turenne, Marie-Carmelle; Bajwa, Ednan; Bell, Todd E.; Cairns, Charles B.; Shoham, Shmuel; Deville, Jaime G.; Feucht, Eric; Feinberg, Judith; Luke, Thomas; Raviprakash, Kanakatte; Danko, Janine; O’Neil, Dorothy; Metcalf, Julia A.; King, Karen; Burgess, Timothy H.; Aga, Evgenia; Lane, H. Clifford; Hughes, Michael D.; Davey, Richard T.
Title: A Randomized Study of Immune Plasma for the Treatment of Severe Influenza Document date: 2017_5_15
ID: 2g22oqf2_30
Snippet: The use of immune plasma has been recommended as a primary therapy for severe respiratory infectious diseases, including influenza, SARS and MERS. [9] However, data supporting these recommendations are weak and limited to case reports, case series, and one case control study. [10] Additionally, a randomized controlled trial of hyper-immune antiinfluenza immunoglobulin did not show any benefit in mortality, ICU stay, or hospital stay. [11] A post-.....
Document: The use of immune plasma has been recommended as a primary therapy for severe respiratory infectious diseases, including influenza, SARS and MERS. [9] However, data supporting these recommendations are weak and limited to case reports, case series, and one case control study. [10] Additionally, a randomized controlled trial of hyper-immune antiinfluenza immunoglobulin did not show any benefit in mortality, ICU stay, or hospital stay. [11] A post-hoc analysis of participants treated within 5 days of symptom onset was reported as demonstrating reduced mortality (0/12 (0%) vs 4/10 (40%), OR, 0.14; p =0.04), though conversely those treated after 5 days had an increased mortality (5/5 (100%) vs 0/7 (0%), no statistical analysis reported).
Search related documents:
Co phrase search for related documents- case control and hospital stay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
- case control and hospital stay ICU stay: 1, 2
- case control and ICU stay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- case control and increase mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- case control and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- case control and mortality benefit: 1, 2
- case control and post hoc analysis: 1
- case control and primary therapy: 1, 2, 3
- case control and recommendation support: 1, 2
- case control and reduce mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- case control and report case: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41
- case control and respiratory infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- case control and statistical analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- case control and symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- case control study and control trial: 1, 2, 3, 4, 5, 6, 7
- case control study and hospital stay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- case control study and ICU stay: 1, 2, 3, 4, 5, 6, 7, 8, 9
- case control study and increase mortality: 1, 2, 3, 4, 5, 6, 7
- case control study and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
Co phrase search for related documents, hyperlinks ordered by date